

Home-based exercise and motivational programme before and after liver transplantation: ExaLT Trial

Submission date 12/05/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 07/06/2022	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 06/10/2025	Condition category Surgery	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Liver disease is the 3rd commonest cause of death in adults of working age and liver transplantation (LT) remains the only cure for liver failure. LT exerts a huge stress on the body and mind, especially in people who are already physically and mentally frail because of their liver disease. We know that being physically frailty prior to surgery results in a longer hospital stay because of postoperative complications and contributes to 1 in 10 patients either dying whilst still on the waiting list or shortly after LT. Exercise is one of the most powerful medical therapies available, with numerous proven benefits to patients with diseases like diabetes, heart disease and cancer. Despite this, exercise is not currently used in patients with liver failure or recovering from LT, due to a lack of robust evidence. Exercise may have the potential to improve the lives of people with liver disease and reduce the side-effects of LT surgery. The current standard of care for NHS patients awaiting LT is an advice leaflet. Evidence-based exercise programmes around the time of transplantation do not exist. Only a few small studies have indicated that supervised, hospital-based exercise can improve physical function and quality of life. We aim to determine the effect of a home-based exercise and motivation-support programme in patients undergoing LT on their quality of life after surgery. We would also like to understand if exercise results in improvements in intricate measures of physical fitness and muscle function that account for changes in quality of life, and how the motivation-support component of the intervention enhances uptake and ongoing engagement of exercise pre and post LT.

Who can participate?

Patients with end-stage liver disease who are on the liver transplant waiting list.

What does the study involve?

We intend to perform a clinical trial, in which patients will be randomly allocated to receive either the home-based exercise/motivation support programme (intervention group) or a patient advice leaflet (control group) whilst on the LT waiting list. The intervention will begin whilst patients are on the LT waiting list and end 6 months after LT. The intervention will consist of regular strength and endurance exercises, tailored to each patient's level of fitness. During clinic visits and via telephone calls a physiotherapist will provide motivational support

throughout the exercise programme. The trial will involve recruiting 266 patients over two years from two LT hospitals in England. We shall assess the effectiveness of the intervention by measuring quality of life before and after the study period in both groups of patients. The intervention will be deemed effective if quality of life scores are higher with the intervention than the control group.

What are the possible benefits and risks of participating?

We do not know how this trial will directly help participants, but it will help improve the care of patients with liver failure (and/or liver cancer), who are waiting or who have had a liver transplant. Participants may feel the indirect benefits of being part of this trial such as receive care which is not standard, improve the patient's experience and knowledge of the liver disease process and receive closer monitoring and follow up. Participants may also feel empowered knowing that their contribution to clinical research will help advance new and improved treatments/services for patients undergoing a liver transplant.

The exercises that participants will be given to do will be matched to their ability and individualised to their needs, however there is still the possibility of sprains or injuries if the exercise are not carried out correctly. Participants can experience temporary pain/discomfort when they have blood taken and may develop a bruise at the site where the needle has sampled blood. To minimise this, additional blood tests for trial purposes will be taken (when possible) at the same time as blood tests as part of their routine clinical care.

In relation to an ongoing COVID pandemic, current government guidelines will be adhered to and local NHS and University procedures will be followed to minimise the risk of exposure to the virus.

Where is the study run from?

University of Birmingham (UK)

When is the study starting and how long is it expected to run for?

June 2021 to May 2026

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?

Dawn Brant, d.p.brant@bham.ac.uk

Study website

<http://www.birmingham.ac.uk/ExaLT>

Contact information

Type(s)

Scientific

Contact name

Dr Dawn Brant

Contact details

Birmingham Clinical Trials Unit (BCTU)
Institute of Applied Health Research
College of Medical and Dental Sciences

Public Health Building
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TT

-
exalt@trials.bham.ac.uk

Type(s)

Principal Investigator

Contact name

Dr Matthew Armstrong

Contact details

University Hospitals Birmingham
Mindelsohn Way
Birmingham
United Kingdom
B15 2TH
+44 121 3714673
matthew.armstrong@uhb.nhs.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

295426

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 52211, NIHR129318, IRAS 295426

Study information

Scientific Title

A phase IIb, randomised-controlled, two-centre clinical trial (ExaLT) on the efficacy of a home-based exercise and motivational programme in patients before and after liver transplantation

Acronym

ExaLT

Study objectives

A remotely monitored 'home-based exercise and theory based motivation support programme' delivered by physiotherapists before and after liver transplantation (LT) (intervention group)

improves the quality of life (physical component score of SF-36v2) in LT recipients compared to a control group using a patient 'exercise' advice leaflet (control group).

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 01/04/2022, Hampshire A REC Board (Temple Quay House, 2 The Square, Temple Quay, Bristol, BS1 6PN, United Kingdom; +44 207 104 8196; hampshirea.rec@hra.nhs.uk), ref: 22/SC/0067

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Quality of life

Participant information sheet

<http://www.birmingham.ac.uk/ExaLT>

Health condition(s) or problem(s) studied

Exercise before and after liver transplant

Interventions

Eligible participants will be randomised 1:1 to receive either:

Group 1: Intervention group. Remotely-monitored home-based exercise and theory-based motivation support programme whilst on the LT waiting list (max. 12 months) through to 24 weeks post-LT.

OR

Group 2: Control group. Patient exercise advice leaflet before and after LT.

The study intervention will be variable due to the unpredictable nature of the timing of Liver transplant (median waiting time 72 days (95% CI 64-80) registered between 2018-2021).

All patients that are transplanted within 52 weeks of randomisation will receive a fixed 24 week intervention after Liver transplant (LT.)

The visits are summarised below:

Phase 1. Participants will attend the hospital (QEUHB or RFH) in line with their routine waiting list clinic appointment (where possible), at baseline (visit 1), weeks 6 (visit 2), 12 (visit 3), 24 (visit 4), 36 (visit 5) and 48 (visit 6). At these visits, a repeat of the baseline assessment, including LFI and DASl, will be undertaken. The results of these assessments, review of the participant exercise diary and discussions with the participant themselves will be used to progress exercises

and revise goals of their Home-based exercise programme (HBEP) if they are in the intervention arm.

The end of the study intervention will be at 52 weeks if the participant has not undergone LT. At this stage, they will be asked if they wish to continue in the study (data collection).

Post Liver Transplant: Phase 2

The trial physiotherapists will review the participant on the post-LT ward, within 48 hours of discharge from ICU. Within 48 hours prior discharge from hospital (or day 10 post-LT if not discharged by this point), a repeat of the baseline assessments, including LFI and DASI, will be undertaken on the ward

Participants will then attend the hospital (QEUHB or RFH), in line with their routine post-LT follow-up clinic appointment (where possible), at weeks 6 post LT (visit 7), week 12 (visit 8), week 24 weeks (visit 9), 48 weeks (visit 10). At these visits, a repeat of the baseline assessment, including LFI and DASI, will be undertaken. Of note, Phase 2 of the HBEP will commence on day 1 of admission to the post-LT ward (i.e. within 24 hours of discharge from ICU) and end 24 weeks after the date of the LT surgery (visit 9).

Intervention Type

Behavioural

Primary outcome measure

Physical component score (PCS) from the short form-36 version 2.0 (SF-36v2) health-related QoL questionnaire at 24 weeks post LT (scale 0-100).

Secondary outcome measures

Key secondary outcome measure:

1. Comprehensive Complication Index at 24 weeks post LT (scale 0-100).

Other secondary outcome measures to be assessed at 24 weeks post LT (unless stated):

2. Mental Component Score (MCS) of SF-36v2 health-related QoL questionnaire
3. Liver Frailty Index (LFI), Duke Activity Score Index (DASI)
4. Pre-LT morbidity (UKELD, MELD-Na, hospital admissions) and mortality (*assessed up to day of LT)
5. Post-LT length of ICU/hospital stay and hospital re-admissions (frequency, duration [days])
6. Post-LT 30, 90, 180 and 365 day mortality
7. Habitual physical activity levels (daily time spent in light, moderate and vigorous intensity physical activity) using Actigraph accelerometers
8. "Dose" of exercise completed (measure of the frequency, intensity and duration of exercise)
9. Adherence to Home-based exercise program (HBEP - intervention arm only)
10. Perceptions of the health care climate (how need supportive/empowering the physiotherapist is), measured using the Health Care Climate Questionnaire (HCCQ)
11. Basic psychological need satisfaction (i.e. feelings of autonomy, relatedness, competence), measured using the Basic Psychological Need Satisfaction in Exercise Scale (PNSE)
12. Self-determined motivation to exercise, using Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2)

Overall study start date

09/06/2021

Completion date

31/05/2026

Eligibility

Key inclusion criteria

1. Adult Patients (aged 18 years or over)
2. Patients listed for a cadaveric, primary liver transplantation (LT) at QEUHB or the RFH
3. Being an out-patient at the time of baseline trial visit (consent)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

266

Total final enrolment

269

Key exclusion criteria

1. Patient listed for Liver Transplant for any of the following reasons:
 - 1.1. Super-urgent Liver Transplant (according to the Kings College criteria)
 - 1.2. Multi-organ transplantation (e.g. combined liver and kidney transplant)
 - 1.3. Live-related donor Liver Transplant
 - 1.4. Re-graft Liver Transplant
2. Patients with an inability to safely comply with the exercise intervention due to the following conditions:
 - 2.1. Severe hepatic encephalopathy (defined as grade 3 or 4; as judged by the principal or nominated co-investigators)
 - 2.2. Oxygen-dependent hepato-pulmonary syndrome
3. Patients without liver failure, including:
 - 3.1. Liver cancer in the absence of cirrhosis
 - 3.2. Polycystic liver disease
 - 3.3. Rare metabolic/genetic conditions (e.g. glycogen storage disorders)
4. Refusal or lacks capacity to give informed consent to participate in the trial, at the point of study visit 1

Date of first enrolment

03/05/2022

Date of final enrolment

28/05/2024

Locations

Countries of recruitment

United Kingdom

Study participating centre

Royal Free Hospital

Pond Street

London

United Kingdom

NW3 2QG

Study participating centre

Queen Elizabeth Hospital Birmingham

Mindelsohn Way

Edgbaston

Birmingham

United Kingdom

B15 2TH

Sponsor information

Organisation

University of Birmingham

Sponsor details

Edgbaston

Birmingham

England

United Kingdom

B15 2TT

+44 7814 650003

researchgovernance@contacts.bham.ac.uk

Sponsor type

University/education

Website

<http://www.birmingham.ac.uk/index.aspx>

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Government

Funder Name

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC)

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

01/06/2027

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		03/09/2024	10/09/2024	Yes	No